Living donor liver transplantation for hepatocellular carcinoma

LAUR Repository

Show simple item record

dc.contributor.author Di Sandro, Stefano
dc.contributor.author Giacomoni, Alessandro
dc.contributor.author Slim, Abdallah
dc.contributor.author Lauterio, Andrea
dc.contributor.author Mangoni, Lacpo
dc.contributor.author Mihaylov, Plamen
dc.contributor.author Pirotta, Vincenzo
dc.contributor.author Aseni, Paolo
dc.contributor.author De Carlis, Luciano
dc.date.accessioned 2019-06-12T06:35:12Z
dc.date.available 2019-06-12T06:35:12Z
dc.date.copyright 2012 en_US
dc.date.issued 2019-06-12
dc.identifier.issn 0172-6390 en_US
dc.identifier.uri http://hdl.handle.net/10725/10783
dc.description.abstract Background/Aims: LDLT may represent a valid therapeutic option allowing several advantages for patients affected by HCC and waiting for liver transplantation (LT). However, some reports show a worse long term survival and disease free survival among patients treated by LDLT for HCC than deceased donor liver transplantation (DDLT) recipients. Methodology: Among 1145 LT patients, 63 received LDLT. From January 2000 to December 2008, 179 patients underwent LT due to HCC, 30 (16.7%) received LDLT and 154 (86.0%) received DDLT. Patients were selected based on the Milan criteria. TACE, radiofrequency ablation, percutaneous alcoholization, or liver resection were applied as downstaging procedures, while on the waiting list. Results: Overall 3- and 5-year survival rate was 77.3% and 68.7% vs. 82.8% and 76.7%, respectively for LDLT and DDLT recipient with not significant differences. Moreover, 3- and 5- years of recurrence free survival rate was 95.5% (LDLT) vs. 90.5% and 89.4% (DDLT) and resulted not significantly different. Conclusions: LDLT guarantees same long term results than DDLT if the selection criteria of candidates are analogues. Milan criteria remains a valid candidate selection tool to obtain optimal long term results in LDLT. An aggressive downstaging policy seems to improve the long-term results in LDLT, thus LRT may be considered useful to prevent tumor progression waiting for transplantation as well as a neoadjuvant therapy for HCC. A literature detailed meta-analysis could definitely clarify if LDLT is an independent risk factor for HCC recurrence. © H.G.E. Update Medical Publishing S.A. en_US
dc.language.iso en en_US
dc.title Living donor liver transplantation for hepatocellular carcinoma en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle the impact of neo-adjuvant treatments on the long term results en_US
dc.author.school SOM en_US
dc.author.idnumber 201801809 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Hepato-Gastroenterology en_US
dc.journal.volume 59 en_US
dc.journal.issue 114 en_US
dc.article.pages 505-510 en_US
dc.keywords Hepatocellular carcinoma
dc.keywords Living donor liver transplantation
dc.keywords Pre-transplant treatments
dc.identifier.doi http://dx.doi.org/10.5754/hge11225 en_US
dc.identifier.ctation Di, S. S., Giacomoni, A., Slim, A., Lauterio, A., Mangoni, I., Mihaylov, P., ... & De, L. C. (2012). Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results. Hepato-gastroenterology, 59(114), 505-510. en_US
dc.author.email abdallah.slim@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://europepmc.org/article/med/22353516 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account